

Can't find Eylea for your next injection? Here are proven tools and tips to locate Eylea in stock near you in 2026.
You rely on Eylea (Aflibercept) injections to protect your vision. So when your retina specialist's office says they're out of stock — or your next appointment gets pushed back — the stress is understandable. Conditions like wet AMD, diabetic macular edema, and retinal vein occlusion don't wait for supply chains to catch up.
The good news is that Eylea is still being manufactured and distributed. The challenge is knowing where it's available right now. In this guide, we'll share practical tools and tips to help you find Eylea in stock near you.
Before we dive into solutions, it helps to understand the problem. Eylea is a biologic medication — made from living cells in specialized facilities. High global demand, manufacturing complexity, and limited biosimilar competition have created intermittent supply constraints since 2023. For a deeper look, read our article on why Eylea is so hard to find in 2026.
Medfinder is a free tool that helps patients locate medications that are in stock near them. Instead of calling practice after practice, you can search for Eylea on Medfinder and see which ophthalmology offices and retina centers currently have it available.
Here's how to use it:
This is especially helpful if your regular retina specialist is out of stock and you need to find another provider quickly.
Eylea isn't dispensed at regular retail pharmacies — it's stocked by ophthalmology and retina practices that administer the injections on-site. If Medfinder doesn't show results near you, try calling:
When you call, ask specifically: "Do you currently have Eylea (Aflibercept) in stock, and can you accommodate a new patient for an injection?"
Some practices receive Eylea shipments on specific days of the week. When you call to schedule, ask:
Being flexible with your schedule — even by a few days — can make the difference between getting your injection on time and waiting weeks.
If you've tried all three tips above and still can't locate Eylea, don't panic. You have options:
Several other anti-VEGF medications treat the same conditions as Eylea. Your retina specialist may recommend switching to Vabysmo (Faricimab), Lucentis (Ranibizumab), or Avastin (Bevacizumab) — either temporarily or long-term. Read our full guide on alternatives to Eylea for more details.
Eylea HD (8 mg Aflibercept) is a higher-dose formulation that may be available when the standard 2 mg version is not. It also allows for longer intervals between injections — up to 16 weeks for some patients — which means fewer doses needed overall.
Regeneron Pharmaceuticals, the maker of Eylea, maintains a patient support line through its Eylea4U program. They may be able to help connect you with a provider that has stock or assist with access. Visit their website or call their support line for help.
This is the most important point. Conditions like wet AMD and diabetic macular edema can worsen rapidly without treatment. Even if you need to temporarily switch to a different anti-VEGF medication, it's almost always better than skipping an injection entirely. Talk to your doctor about the best backup plan for your situation.
Here are a few proactive steps to avoid future disruptions:
Finding Eylea in stock takes a bit more effort in 2026 than it should, but the tools and strategies above can help. Use Medfinder as your first step, reach out to specialty practices, stay flexible with scheduling, and always keep your retina specialist in the loop. Your vision is too important to leave to chance.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.